Loading clinical trials...
Loading clinical trials...
This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020. The purpose of Part B is...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT07470151 · System Lupus Erythematosus(SLE), Scleroderma, and more
NCT06801119 · Systemic Lupus Erythematosus, Scleroderma, and more
NCT04402086 · Rheumatic Diseases, Adult Onset Still Disease, and more
NCT07256418 · Scleroderma
NCT07343115 · Systemic Scleroderma
Local Institution
Scottsdale, Arizona
Local Institution
Los Angeles, California
Local Institution
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions